$TWST

Cho Dennis sold $30K of TWST

Cho Dennis (See Remarks) sold 346 shares of Twist Bioscience Corp (TWST) at $87.32 on 2026-06-22.

Original reporting
SEC EDGAR · Cho Dennis
Published Jun 24, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity (346-share open-market sale) but does not introduce new operational or financial information about TWST.

02

Market read

Traders may monitor for insider-selling trends, but this single small sale is unlikely to drive a durable repricing without other catalysts.

03

What to watch

The article does not state motivations (taxes, diversification, planned liquidity) and provides no comparison to prior insider activity beyond the single transaction.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-06-24 (after-hours/late day disclosure) for a 2026-06-22 sale

Background

This is an SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience officer Cho Dennis filed a Form 4 showing an open-market sale of 346 shares at $87.3224 on 2026-06-22.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless followed by additional insider selling or new fundamentals.

Evidence & confidence

The filing is a small, non-10b5-1 sale with disclosed price and post-transaction holdings, but it does not include new company performance, guidance, or regulatory/contract events.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Insider sales are often liquidity-driven; without a pattern or accompanying 10b5-1/compensation context, the signal may be overstated.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction; officer Cho Dennis sold 346 shares at $87.3224.

  • Cho Dennis

    Officer who executed the open-market sale; holdings after transaction: 119,346 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.